…About two-thirds of patients with trigeminal neuralgia (TN) may respond to injections of botulinum toxin type A (BTX-A), according to the results of a double-blind, placebo-controlled trial (Wu et al. Cephalalgia 2012;32:443-450). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – The initial dose-ranging study of natalizumab indicated that 1-3 mg/kg was clinically effective (Sheremata et al. Neurology 1999;52:1072-1074) and this was the dose selected by the Natalizumab MS Trial Group (O’Connor et al. Neurology 2004;62:2038-2043). Subscribe to read more It takes 30 seconds or login using your email address Please enter t…
…email address Please enter the email address that you registered the newsletter with Continue…
REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, NEW ORLEANS LA, APRIL 21-28, 2012 – A number of reviews of celiac disease (CD) have reported on an increased prevalence of neurological and psychiatric symptoms, such as headache disorders, cerebellar ataxia, peripheral neuropathies, vestibular dysfunction, depression and personality changes (Burk et al. Mov Disord 2009;24:2358-2362; Zelnik et al. Pediatrics 2004;113:1672-1676)….